Allogene Therapeutics Inc (NASDAQ:ALLO)’s stock price shot up 5.3% on Monday . The company traded as high as $27.71 and last traded at $27.67, 249,653 shares changed hands during mid-day trading. A decline of 42% from the average session volume of 429,294 shares. The stock had previously closed at $26.27.

A number of brokerages have weighed in on ALLO. Oppenheimer began coverage on Allogene Therapeutics in a research report on Friday, May 3rd. They issued an “outperform” rating and a $45.00 price target on the stock. Zacks Investment Research cut Allogene Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 12th. Stifel Nicolaus began coverage on Allogene Therapeutics in a research report on Wednesday, May 22nd. They issued a “hold” rating and a $27.00 price target on the stock. Roth Capital began coverage on Allogene Therapeutics in a report on Wednesday, June 5th. They set a “neutral” rating and a $26.00 target price on the stock. Finally, Guggenheim began coverage on Allogene Therapeutics in a report on Thursday, May 30th. They set a “neutral” rating on the stock. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $36.10.

The firm has a fifty day moving average price of $28.29 and a 200 day moving average price of $28.41. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.05. The company has a market cap of $3.20 billion and a P/E ratio of -4.21.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Wednesday, August 7th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.06. On average, sell-side analysts anticipate that Allogene Therapeutics Inc will post -1.94 earnings per share for the current year.

In other news, insider Alison Moore sold 48,828 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $26.76, for a total transaction of $1,306,637.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 36.50% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. First Trust Advisors LP lifted its stake in shares of Allogene Therapeutics by 0.4% during the first quarter. First Trust Advisors LP now owns 101,816 shares of the company’s stock valued at $2,944,000 after acquiring an additional 375 shares during the period. Rhumbline Advisers increased its holdings in shares of Allogene Therapeutics by 1.8% in the first quarter. Rhumbline Advisers now owns 31,348 shares of the company’s stock worth $906,000 after acquiring an additional 560 shares in the last quarter. TD Asset Management Inc. increased its holdings in shares of Allogene Therapeutics by 2.4% in the first quarter. TD Asset Management Inc. now owns 25,643 shares of the company’s stock worth $741,000 after acquiring an additional 600 shares in the last quarter. Morgan Stanley increased its holdings in shares of Allogene Therapeutics by 7.7% in the second quarter. Morgan Stanley now owns 9,707 shares of the company’s stock worth $260,000 after acquiring an additional 691 shares in the last quarter. Finally, UBS Asset Management Americas Inc. increased its holdings in shares of Allogene Therapeutics by 1.1% in the second quarter. UBS Asset Management Americas Inc. now owns 200,267 shares of the company’s stock worth $5,377,000 after acquiring an additional 2,142 shares in the last quarter. 52.83% of the stock is currently owned by institutional investors and hedge funds.

About Allogene Therapeutics (NASDAQ:ALLO)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

Further Reading: How is a price target determined?

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.